Publication Date:
2019-11-13
Description:
Background: Patients with Philadelphia+ Acute Lymphoid Leukemia (Ph+ ALL) respond to the same tyrosine kinase inhibitors (TKIs) that work against Chronic Myeloid Leukemia (CML). However, the dominant BCR-ABL breakpoint is the e1a2 (p190) minor transcript with the e13a2/e14a2 (p210) major transcripts, accounting for 20-30% of the ALL patients, together with
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine